Jill M. Broadfoot
2020 - aTYR PHARMA
In 2020, Jill M. Broadfoot earned a total compensation of $698.8K as Chief Financial Officer at aTYR PHARMA, a 54% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $138,985 |
|---|---|
| Option Awards | $182,671 |
| Salary | $365,750 |
| Other | $11,374 |
| Total | $698,780 |
Broadfoot received $365.8K in salary, accounting for 52% of the total pay in 2020.
Broadfoot also received $139K in non-equity incentive plan, $182.7K in option awards and $11.4K in other compensation.
Rankings
In 2020, Jill M. Broadfoot's compensation ranked 9,986th out of 13,090 executives tracked by ExecPay. In other words, Broadfoot earned more than 23.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,986 out of 13,090 | 24th |
Division Manufacturing | 4,295 out of 5,621 | 24th |
Major group Chemicals And Allied Products | 1,765 out of 2,254 | 22nd |
Industry group Drugs | 1,545 out of 1,954 | 21st |
Industry Biological Products, Except Diagnostic Substances | 352 out of 411 | 14th |
Source: SEC filing on March 23, 2021.
Broadfoot's colleagues
We found two more compensation records of executives who worked with Jill M. Broadfoot at aTYR PHARMA in 2020.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019